Inclusion Criteria:

- Patients of either gender, aged at least 18 years.

- Karnofsky status equal or greater than 60.

- Life expectancy of at least 12 weeks.

- Histologically and/or clinically confirmed and/or suspicious of NET.

- Somatostatin-analogue scintigraphies scan with result (positive or negative) within
the last 4 weeks.

- Recent Blood test results up to 2-3 weeks as follows:(WBC:equal/higher 2*109/L;
Haemoglobin: equal/higher 8.0g/Dl; Platelets: equal/higher 50x109/L; ALT, AST, AP:
equal/lower 5 times ULN; Bilirubin: equal/lower 3 times ULN; Serum creatinine: within
normal range or <120μmol/L for patients aged 60 years or older.

- Negative pregnancy test in women capable of child-bearing.

Exclusion Criteria:

- Known hypersensitivity to DOTA, to 68Gallium, to Octreotate or to any of the
excipients of 68Ga-DOTATATE.

- Therapeutic use of any somatostatin analogue, including Sandostatin® LAR (within 28
days) and Sandostatin® (within 2 days) prior to study imaging. If a patient is on
Sandostatin® LAR a wash-out phase of 28 days is required before the injection of the
study drug.

- Pregnant or breast-feeding women.

- Current somatic or psychiatric disease/condition that may interfere with the
objectives and assessments of the study.